BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10367809)

  • 1. Cost-effectiveness of interferon treatment for hepatitis C.
    Henley E
    JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of interferon treatment for hepatitis C.
    van Leeuwen DJ
    JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
    [No Abstract]   [Full Text] [Related]  

  • 3. [Economic evaluation of combined therapy in chronic hepatitis C].
    Casado MA; Buti M; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
    Yoshida H; Tateishi R; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of treatment for chronic hepatitis C.
    Koff RS
    J Hepatol; 1999; 31 Suppl 1():255-8. PubMed ID: 10622598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doing battle with HCV.
    Fimmel CJ
    Am J Gastroenterol; 2000 Mar; 95(3):582-3. PubMed ID: 10710043
    [No Abstract]   [Full Text] [Related]  

  • 8. Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
    Korr M
    R I Med J (2013); 2014 Jul; 97(7):29-30. PubMed ID: 24983018
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
    Kuwabara H; Westerhout K; Treur M; Cerri K; Mahlich J; Yatsuhashi H
    J Med Econ; 2015; 18(7):502-11. PubMed ID: 25763827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
    Poordad F; Theodore D; Sullivan J; Grotzinger K
    J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis B in india: what is the cost of life?
    Anand AC
    Natl Med J India; 2002; 15(6):317-9. PubMed ID: 12540063
    [No Abstract]   [Full Text] [Related]  

  • 13. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
    Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
    J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Bernstein D
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559948
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of treatment for chronic hepatitis C infection.
    Dore GJ; Thein HH
    JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559947
    [No Abstract]   [Full Text] [Related]  

  • 17. 'HepConomics': cost-effective, indeed, but how can we pay for it?
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Viral Hepat; 2015 Aug; 22(8):682. PubMed ID: 25727161
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia.
    Warren E; Wright A; Jones B
    Value Health; 2014 Dec; 17(8):792-800. PubMed ID: 25498774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2.
    Iwasaki Y; Tanaka H; Ikeada H; Okamoto R; Araki Y; Yabushita K; Kobashi H; Kariyama K; Kawaguchi M; Takaguchi K; Sakata T; Ando M; Sakaguchi K; Aoki N; Shiratori Y
    Scand J Gastroenterol; 2011 Jan; 46(1):79-90. PubMed ID: 20822376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economics of chronic hepatitis B and hepatitis C.
    Rajendra A; Wong JB
    J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.